Aethlon Medical, Inc. (NASDAQ:AEMD – Get Rating) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 186,700 shares, a drop of 17.7% from the February 13th total of 226,800 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is presently 0.2 days.
Analyst Ratings Changes
Several brokerages recently weighed in on AEMD. StockNews.com began coverage on shares of Aethlon Medical in a research report on Thursday. They set a “sell” rating for the company. Maxim Group cut shares of Aethlon Medical from a “buy” rating to a “hold” rating in a report on Tuesday, November 15th.
Aethlon Medical Trading Down 8.0 %
NASDAQ:AEMD opened at $0.41 on Monday. Aethlon Medical has a 12 month low of $0.23 and a 12 month high of $2.46. The company has a market cap of $9.30 million, a PE ratio of -0.55 and a beta of 1.25. The company has a 50 day simple moving average of $0.49 and a two-hundred day simple moving average of $0.55.
Institutional Investors Weigh In On Aethlon Medical
Large investors have recently added to or reduced their stakes in the stock. Buckingham Strategic Partners bought a new stake in shares of Aethlon Medical during the 3rd quarter valued at $29,000. Natixis bought a new stake in shares of Aethlon Medical during the 2nd quarter valued at $28,000. Vanguard Group Inc. grew its position in shares of Aethlon Medical by 112.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock valued at $613,000 after acquiring an additional 558,596 shares during the period. Renaissance Technologies LLC grew its position in shares of Aethlon Medical by 11.6% during the 1st quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock valued at $395,000 after acquiring an additional 28,097 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of Aethlon Medical during the 3rd quarter valued at $72,000. Institutional investors own 11.86% of the company’s stock.
Aethlon Medical Company Profile
Aethlon Medical, Inc is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI.
Receive News & Ratings for Aethlon Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aethlon Medical and related companies with MarketBeat.com’s FREE daily email newsletter.